专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20230265172A1 HUMANIZED ANTIBODY SPECIFIC TO BACILLUS ANTHRACIS PROTECTIVE ANTIGEN AND PREPARATION METHOD THEREOF 审中-公开
公开(公告)号：US20230265172A1
公开(公告)日：2023-08-24
申请号：US18007008
申请日：2021-07-26
申请人： AGENCY FOR DEFENSE DEVELOPMENT
发明人： Chi-Ho Yu , Chang-Hwan Kim , Gyeung-Haeng Hur , Seong-Tae Jeong , Dong-Hyun Song , Hae-Eun Joe , Na-Young Kim , Jun-Young Choi , Young-Kee Shin , Hyun-Ho Jeong , Seung-Chul Jun
IPC分类号： C07K16/12
CPC分类号： C07K16/1278 , C07K2317/24 , C07K2317/21 , C07K2317/622 , C07K2317/76 , A61K2039/505
摘要： The present invention relates to a humanized antibody specific to a Bacillus anthracis protective antigen and a preparation method thereof. An antibody library is created by obtaining a Bacillus anthracis protective antigen antibody of a monkey from immune cells obtained by immunizing a Bacillus anthracis protective antigen, an antibody specific to the Bacillus anthracis protective antigen is selected from the created antibody library, and, on the basis of the antibody, a humanized antibody specific to the Bacillus anthracis protective antigen is finally selected by creating a humanized antibody library against a Bacillus anthracis protective antigen. The selected humanized antibody specific to the Bacillus anthracis protective antigen exhibits very high Bacillus anthracis protective antigen affinity and toxin neutralization capacity and has a neutralizing effect in the body before and after exposure to Bacillus anthracis, and thus can be used as a therapeutic composition for treating or preventing an anthrax.

2. 发明申请

US20190211069A1 Nucleic Acids for Single-Domain Antibodies with Thermal Stability Under Cytoplasmic Expression 审中-公开
公开(公告)号：US20190211069A1
公开(公告)日：2019-07-11
申请号：US16365945
申请日：2019-03-27
申请人： The Government of the United States of America, as represented by the Secretary of the Navy
发明人： Daniel Zabetakis , George P. Anderson , Ellen R. Goldman , Kendrick Turner , P. Audrey Brozozog Lee
IPC分类号： C07K14/47 , C07K16/16 , C07K16/12
CPC分类号： C07K14/47 , C07K16/1271 , C07K16/1278 , C07K16/16 , C07K2317/569 , C07K2317/94 , C07K2319/00
摘要： A nucleic acid encodes a single-domain antibody (sdAb) is produced by causing a bacteria to express the sdAb into cytoplasm of the bacteria, wherein the sdAb is expressed as a fusion protein with the acid tail of α-synuclein. In embodiments, the protein is free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation.

3. 发明申请

US20180111981A1 Monoclonal Antibodies that Neutralize Anthrax Toxins 审中-公开
公开(公告)号：US20180111981A1
公开(公告)日：2018-04-26
申请号：US15411065
申请日：2017-01-20
申请人： The USA, as represented by the Secretary, Dept. of Health and Human Services
发明人： Zhaochun CHEN , Robert H. PURCELL , Suzanne U. EMERSON , Stephen H. LEPPLA , Mahtab MOAYERI
IPC分类号： C07K16/12 , G01N33/569 , C07K16/40 , G01N33/573 , A61K51/10 , A61K39/00
CPC分类号： C07K16/1278 , A61K51/1009 , A61K2039/505 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56911 , G01N33/573 , G01N2333/32 , G01N2333/954 , G01N2469/10
摘要： The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

4. 发明申请

US20170327860A1 METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES 审中-公开
公开(公告)号：US20170327860A1
公开(公告)日：2017-11-16
申请号：US15496807
申请日：2017-04-25
申请人： Merus N.V.
发明人： Cornelis Adriaan DE KRUIF , Linda Johanna Aleida HENDRIKS , Ton LOGTENBERG
IPC分类号： C12P21/00 , A61K39/395 , A61K39/40 , C07K16/12 , C07K16/46 , C07K16/36 , C07K16/28 , C07K16/26 , C07K16/18 , A61K39/00
CPC分类号： C12P21/005 , A61K39/395 , A61K39/3955 , A61K39/40 , A61K2039/507 , C07K16/12 , C07K16/1278 , C07K16/1282 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/2809 , C07K16/283 , C07K16/2866 , C07K16/2896 , C07K16/36 , C07K16/468 , C07K2317/14 , C07K2317/31 , C07K2317/526 , C07K2317/56 , C07K2317/94
摘要： The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

5. 发明授权

US09580492B2 Monoclonal antibodies that neutralize anthrax toxins 有权
标题翻译：中和炭疽毒素的单克隆抗体
公开(公告)号：US09580492B2
公开(公告)日：2017-02-28
申请号：US14595475
申请日：2015-01-13
申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
发明人： Zhaochun Chen , Robert H. Purcell , Suzanne U. Emerson , Stephen H. Leppla , Mahtab Moayeri
IPC分类号： G01N33/573 , C07K16/12 , C07K16/40 , A61K51/10 , G01N33/569 , A61K39/00
CPC分类号： C07K16/1278 , A61K51/1009 , A61K2039/505 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56911 , G01N33/573 , G01N2333/32 , G01N2333/954 , G01N2469/10
摘要： The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
摘要翻译：本发明涉及结合或中和炭疽致死因子（LF），水肿因子（EF）和/或保护性抗原（PA）的单克隆抗体。本发明提供了这样的抗体，这种抗体的保留了炭疽毒素结合能力的片段，完全人或人源化抗体，保留了炭疽毒素结合能力，以及包含这些抗体的药物组合物。本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。另外，本发明提供了使用本发明的抗体和核酸的预防，治疗和诊断方法。

6. 发明授权

US09556255B2 Toxin genes and methods for their use 有权
标题翻译：毒素基因及其使用方法
公开(公告)号：US09556255B2
公开(公告)日：2017-01-31
申请号：US13893763
申请日：2013-05-14
申请人： Athenix Corporation
发明人： Kimberly S. Sampson , Daniel J. Tomso
IPC分类号： C12N15/82 , C07K14/325 , C07K16/12
CPC分类号： C07K14/325 , A01N37/18 , C07K16/1278 , C12N15/8286 , Y02A40/162
摘要： Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:61-121 and 133-141, or the nucleotide sequence set forth in SEQ ID NO:1-60, 124-132, and 142-283, as well as variants and fragments thereof.
摘要翻译：提供了赋予细菌，植物，植物细胞，组织和种子的杀虫活性的组合物和方法。提供了包含δ-内毒素多肽的编码序列的组合物。编码序列可用于DNA构建体或表达盒中，用于在植物和细菌中转化和表达。组合物还包括转化的细菌，植物，植物细胞，组织和种子。特别地，提供了分离的δ-内毒素核酸分子。另外，包括对应于多核苷酸的氨基酸序列，以及与这些氨基酸序列特异性结合的抗体。特别地，本发明提供了分离的核酸分子，其包含编码SEQ ID NO：61-121和133-141所示的氨基酸序列的核苷酸序列或SEQ ID NO：1-60,124所示的核苷酸序列 -132和142-283，以及其变体和片段。

7. 发明申请

US20160368972A1 Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein 审中-公开
标题翻译：用重组中和结合蛋白治疗受试者的方法，组合物和试剂盒
公开(公告)号：US20160368972A1
公开(公告)日：2016-12-22
申请号：US15191739
申请日：2016-06-24
申请人： TUFTS UNIVERSITY
发明人： Charles B. Shoemaker
IPC分类号： C07K16/12 , C07K16/16
CPC分类号： C07K16/1282 , A61K2039/505 , A61K2039/507 , C07K16/1228 , C07K16/1278 , C07K16/16 , C07K16/18 , C07K2317/22 , C07K2317/31 , C07K2317/569 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/40
摘要： Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes a disease agent that is a toxin, for example a Clostridium difficile toxin, a Shiga toxin, a ricin toxin, or an anthrax toxin.
摘要翻译：提供方法，组合物和试剂盒用于使用包含至少一种重组结合蛋白或结合蛋白的表达来源的药物组合物治疗暴露于或处于暴露于疾病的风险中的受试者，其中所述结合蛋白中和疾病作为毒素的试剂，例如艰难梭菌毒素，志贺毒素，蓖麻毒素或炭疽毒素。

8. 发明授权

US09512434B2 Glycosylated protein expression in prokaryotes 有权
标题翻译：原核生物中糖基化蛋白的表达
公开(公告)号：US09512434B2
公开(公告)日：2016-12-06
申请号：US14630308
申请日：2015-02-24
申请人： Cornell Research Foundation, Inc.
发明人： Matthew Delisa , Cassandra Guarino , Thomas Mansell , Adam Fisher
IPC分类号： C12N15/70 , C12N9/10 , C12N9/14
CPC分类号： C12N15/70 , C07K16/1278 , C07K2317/21 , C07K2317/41 , C12N9/1048 , C12N9/1051 , C12N9/14 , C12P21/005 , C12Y204/01132 , C12Y204/01142 , C12Y204/01255 , C12Y204/01257 , C12Y306/03001
摘要： The present invention relates to a prokaryotic host cell comprising eukaryotic glycosyltransferase activity, where the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GlcNAc transferase activity and eukaryotic mannosyltransferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the present invention pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or on the surface of a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format. A glycosylated antibody comprising an Fv portion which recognizes and binds to a native antigen and an Fc portion which is glycosylated at a conserved asparagine residue is also disclosed.
摘要翻译：本发明涉及包含真核糖基转移酶活性的原核宿主细胞，其中真核糖基转移酶活性是真核的二酰基连接的UDP-GlcNAc转移酶活性和真核的甘露糖基转移酶活性。还公开了通过提供包含真核糖基转移酶活性的原核宿主细胞并在有效产生糖基化蛋白的条件下培养原核宿主细胞来生产糖基化蛋白的方法。本发明的另一方面涉及通过在细菌表面上表达一种或多种聚糖以在细菌表面上或噬菌体的表面上附着一个或多个聚糖上的标记物来筛选细菌或噬菌体的方法衍生自细菌，并以高通量格式分析标签。还公开了包含识别和结合天然抗原的Fv部分的糖基化抗体和在保守的天冬酰胺残基处被糖基化的Fc部分。

9. 发明申请

US20160347830A1 IMMUNOGLOBULIN AGAINST THE ANTHRAX TOXIN 审中-公开
标题翻译：免疫球蛋白对ANTHRAX毒素
公开(公告)号：US20160347830A1
公开(公告)日：2016-12-01
申请号：US15111256
申请日：2015-01-16
申请人： LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES , ETAT FRANÇAIS REPRÉSENTÉ PAR LE DIRECTEUR CENTRAL DU SERVICE DE SANTÉ DES ARMÉES
发明人： Christian Behrens , Philippe Klein , Denis Hoguet
IPC分类号： C07K16/12 , G01N33/569 , A61K47/48
CPC分类号： C07K16/1278 , A61K39/40 , A61K47/6835 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92 , G01N33/56911 , G01N2333/32 , A61K2300/00
摘要： The present invention relates to a class-G immunoglobulin against the anthrax toxin protective antigen (PA), or one of the fragments of same, comprising at least: a variable heavy-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 1, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 1, and comprising the amino acids. Leucine in position 51 and Glycine in position 67, and a variable light-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 2, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 2, and comprising a Leucine amino acid in position 55. The invention also relates to the uses of such an immunoglobulin.
摘要翻译：本发明涉及针对所述炭疽毒素保护性抗原（PA）的G类免疫球蛋白或其相应的片段之一，其至少包含：包含由序列SEQ ID NO所示的氨基酸序列的可变重链区域：1，或包含与序列SEQ ID NO：1具有至少90％同一性并包含氨基酸的氨基酸序列。位置51的亮氨酸和位置67的甘氨酸，以及含有由序列SEQ ID NO：2表示的氨基酸序列的可变轻链区域，或包含与序列SEQ ID NO：具有至少90％同一性的氨基酸序列：2，并且包含位置55的亮氨酸。本发明还涉及这种免疫球蛋白的用途。

10. 发明授权

US09458228B2 Gram-positive bacteria specific binding compounds 有权
公开(公告)号：US09458228B2
公开(公告)日：2016-10-04
申请号：US14728826
申请日：2015-06-02
申请人： Genentech, Inc. , AIMM Therapeutics B.V.
发明人： Tim Beaumont , Mark Jeroen Kwakkenbos , Eric J. Brown , John Hiroshi Morisaki , Wouter L. W. Hazenbos , Sanjeev Mariathasan , Kimberly Kajihara , Yi Xia
IPC分类号： C07K16/12
CPC分类号： G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26
摘要： The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式